Story
Expedia Stock Slides After Morgan Stanley Initiates With 'Underweight' Rating

Summary
Shares of Expedia Group slid in pre-market trading after Morgan Stanley initiated coverage with a bearish 'Underweight' rating and a $235 price target, citing slowing user growth and competitive disadvantages.
Expedia Group (EXPE) shares fell 2.7% in pre-open trading after Morgan Stanley initiated coverage on the online travel company with a bearish outlook. The bank assigned an 'Underweight' rating and a price target of $235, implying a potential downside of approximately 20% from the stock's previous closing price.
Rationale Behind the Bearish Call
Morgan Stanley's analysis pointed to significant concerns regarding user engagement and competitive positioning. The firm highlighted that Expedia's monthly active user (MAU) growth decelerated to 0% in the second quarter of 2026, a stark contrast to its peers.
Key points from the initiation note include:
- Slowing User Growth: The flat user growth at Expedia compares unfavorably to the 6% MAU growth reported by Booking.com and 10% by Airbnb over the same period.
- Competitive Disadvantage: The bank's framework placed Expedia at the bottom for consumer supply differentiation. Its inventory is heavily weighted toward commoditized segments like chain hotels and air travel.
- AI Disruption Risk: These core segments are seen as increasingly vulnerable to disruption from emerging AI-powered travel tools, posing a long-term threat to Expedia's business model.
AdMarket Context and Analyst Sentiment
The drop in Expedia's stock is a company-specific event, not the result of a broader market downturn. Major indices, including the S&P 500 and Nasdaq, were trading modestly higher during the same pre-market session, according to market data.
Morgan Stanley's bearish initiation stands in contrast to more optimistic views recently issued by other Wall Street firms. Analysts at Evercore ISI, BTIG, and Oppenheimer had previously set bullish price targets following Expedia's strong Q2 2026 earnings report and its decision to raise full-year guidance.
Read next
More on Stocks
Electra Therapeutics IPO Poised to Price Above Midpoint on Strong Investor Demand
The biotechnology company is expected to price its initial public offering in the upper half of its $14 to $16 range, following significant interest from institutional investors, according to reports.

Vicor Shares Surge 15%, But Record Put Volume Signals Investor Caution
Shares of Vicor Corporation rallied over 15% on Thursday, yet options market data revealed a record volume of put contracts, suggesting some investors are betting against the sustainability of the surge.

Generac Stock Surges, Options Buzz After Securing Amazon as Data Center Client
Generac Holdings announced a multi-billion dollar agreement to supply industrial generators to Amazon's data centers, causing its stock to rally and igniting significant short-term options trading.

Moroccan All Shares Index Slips to One-Month Low on Banking, Mining Weakness
Morocco's main stock index, the Moroccan All Shares, closed down 0.17% on Thursday, hitting its lowest point in a month. The decline was primarily driven by losses in the banking, mining, and utilities sectors.